FDA emergency approval for antibody cocktail for Covid treatment

The US Food and Drug Administration (FDA) granted the biotech company Regeneron emergency approval for its antibody cocktail for the treatment of Covid-19 in the US on Saturday. This allows the cocktail with two antibodies to be used to treat patients aged twelve and over who are at risk of developing severe Covid 19 symptoms. Patients who are in the hospital or need oxygen should not be allowed to have the drug.

For mild to moderate symptoms

The FDA granted approval after a clinical trial of 799 adults with mild to moderate Covid-19 symptoms who were out of the hospital. According to the New York Times, Regeneron received more than $ 500 million (around 421.5 million euros) from the US government for the development of the drug. The government will provide the first 300,000 cans free of charge. However, patients may have to pay health care facilities to have the drug administered, the drug maker said in a statement.

Reduction of the viral load

The antibody cocktail is supposed to prevent the virus from entering the cell. According to the company, the treatment leads to a reduction in the viral load, i.e. the amount of detectable virus, and a faster resolution of symptoms. The test persons whose immune systems had not yet produced their own antibodies against the virus benefited the most. The antibodies are directed against two regions of the spike protein on the surface of the Sars-CoV-2 virus.

After his recovery from Covid-19, US President Donald Trump advertised the treatment of the disease with Regeneron’s antibody cocktail in October. The drug is not a treatment method, but a “cure” and a “miracle” that should soon be available to everyone, he had promised.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.